Cyclosporin assays, metabolite cross-reactivity, and pharmacokinetic monitoring.

The range of cyclosporin (CsA) immunoassays has become the mainstay in many therapeutic drug monitoring laboratories for delivering CsA concentration data to support clinical care of patients after transplantation. However, these assays have been criticized because of the varying degree of CsA-metabolite interferences that introduce analytical errors. The introduction of another such CsA assay (on the AXSyM analyzer) has been considered, as the manufacturer has represented it as having a low CsA-metabolite cross-reactivity profile compared with chromatographic methods. A case is presented to question how this apparent result was obtained in view of the method using the same antibody as another CsA method from the same manufacturer (fluorescence polarizaton immunoassay on the TDx analyzer) which is well known to have poor performance in regard to CsA-metabolite cross-reactivity. The implications for this problem may be even more serious as more patients are monitored using the CsA AUC strategies, rather than the traditional trough concentration approach. Such issues reinforce the need for the clinical laboratory to be critical of methods offered commercially based on scientific/pharmacologic skills.

[1]  W. Steimer.  Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? , 1999, Clinical chemistry.

[2]  P. Wallemacq,et al.  Evaluation of the new AxSYM cyclosporine assay: comparison with TDx monoclonal whole blood and Emit cyclosporine assays. , 1999, Clinical chemistry.

[3]  C. Marsh.  Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group. , 1995, Therapeutic drug monitoring.

[4]  V. Armstrong,et al.  Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. , 1998, Clinical chemistry.

[5]  J. Kovarik,et al.  Cyclosporine monitoring in patients with renal transplants: two- or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. , 1998, Therapeutic drug monitoring.

[6]  R. Morris,et al.  Survey of cyclosporine therapeutic ranges, assay methodology, and use of 'sparing agents' in Australasian transplant centers. , 1997, Therapeutic drug monitoring.

[7]  B. Kahan,et al.  Abbreviated AUC strategy for monitoring cyclosporine microemulsion therapy in the immediate posttransplant period. , 1996, Transplantation proceedings.

[8]  L. Rutzky,et al.  Challenges in Cyclosporine Therapy: The Role of Therapeutic Monitoring by Area Under the Curve Monitoring , 1995, Therapeutic drug monitoring.

[9]  M. Oellerich,et al.  Lake Louise Consensus Conference on Cyclosporin Monitoring in Organ Transplantation: Report of the Consensus Panel , 1995, Therapeutic drug monitoring.

[10]  D. Holt,et al.  Optimizing the use of cyclosporine in renal transplantation. , 1995, Clinical biochemistry.

[11]  R. Morris.  Australian Cyclosporin Therapeutic Monitoring Method Survey: 1993 , 1994, Therapeutic drug monitoring.

[12]  S. Tett,et al.  Cyclosporin A Monitoring in Australia: Consensus Recommendations , 1994, Therapeutic drug monitoring.

[13]  B. Kahan,et al.  Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation , 1993, Clinical pharmacology and therapeutics.

[14]  K. Ilett,et al.  Comparison of cyclosporine measurement in whole blood by high-performance liquid chromatography, monoclonal fluorescence polarization immunoassay, and monoclonal enzyme-multiplied immunoassay. , 1992, Therapeutic drug monitoring.

[15]  R. Morris,et al.  Specific Enzyme‐Multiplied Immunoassay and Fluorescence Polarization Immunoassay for Cyclosporin Compared with Cyclotrac [125I]Radioimmunoassay , 1992, Therapeutic drug monitoring.

[16]  K. Copeland,et al.  Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. , 1990, Clinical chemistry.

[17]  L. Shaw,et al.  Canadian Consensus Meeting on cyclosporine monitoring: report of the consensus panel. , 1990, Clinical chemistry.

[18]  L. Shaw,et al.  Consensus document: Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. , 1990, Transplantation proceedings.

[19]  B. Kahan,et al.  Cyclosporine Monitoring in Renal Transplantation: Area Under the Curve Monitoring Is Superior to Trough‐Level Monitoring , 1989, Therapeutic drug monitoring.

[20]  L. Demers,et al.  Critical issues in cyclosporine monitoring: report of the Task Force on Cyclosporine Monitoring. , 1987, Clinical Chemistry.